Opportunities & Challenges toward the Clinical Application of ctDNA MRD Testing in Solid Cancers

This webinar is a recorded presentation of a live broadcast and includes a pre-test, the presentation, handout, and a post-test. Continuing education credit is available for the webinar.

This interactive webinar is part 3 of the 8 part Utility of Cell-Free DNA in the Clinic Series.


This presentation will cover the evidence that circulating tumor DNA (ctDNA) minimal residual disease (MRD) can predict the development of cancer relapse in solid tumors and guide treatment personalization. In addition, we will discuss key issues for clinical implementation of ctDNA MRD testing, including the biology of ctDNA release, accounting for technical and biological background, determining the ideal timing of blood draws, and choosing a clinical assay.

Learning Objectives:

    1. Identify challenges, and list possible solutions, unique to cfDNA assay validation.

    2. Discuss opportunities for circulating tumor DNA assessment in oncology practices.

    3. Discuss limitations of ctDNA assessment in oncology practices.

Everett Moding, MD, PhD
Lynette M. Sholl, MD

Recording Date: September 28, 2021
Duration: 1 hr
Level of Instruction: Basic
CME/CMLE credit: 1.00 hour

Last Day to Claim Credit: December 31, 2023

Continuing Education Credit Information

Physicians (ACCME)           

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the Association for Molecular Pathology.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this live to enduring activity for a maximum of 8.00 AMA PRA Category 1 CreditsTM (1.00 CE for each webinar). Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Medical Laboratory Education (CMLE)

This activity has been planned and implemented in accordance with the Amedco and joint provider-ship of the ASC and the Association for Molecular Pathology (AMP). Course number 7013.

Supported by an educational grant from AstraZeneca   

Note: Join the AMP Family for discounted access to the most current educational resources!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentation